Table of Contents

1. What Is CAR-T Cell Therapy?
2. Types of CAR-T Cell Therapy
3. Step-by-Step Procedure
4. Cost of CAR-T Cell Therapy in India
5. Who Needs This Therapy (Indications)
6. Risks and Side Effects
7. Benefits of CAR-T Therapy
8. Recovery Timeline and Aftercare
9. Top Hospitals in India
10. Frequently Asked Questions

1. What Is CAR-T Cell Therapy?
   Chimeric Antigen Receptor T-cell (CAR-T) therapy is a form of personalized cancer immunotherapy. Instead of using drugs or radiation to attack a
   tumor from the outside, doctors reprogram the patient’s own immune cells to recognize and destroy cancer cells from within.
   In simple terms: T-cells (a type of white blood cell) are collected from the patient’s blood, genetically modified in a laboratory to carry a new
   receptor — the “chimeric antigen receptor” — and then multiplied into millions of copies. These engineered cells are infused back into the patient,
   where they seek out and attack cancer cells bearing a matching marker, most commonly the CD19 or BCMA protein found on certain blood cancer
   cells.

2. Types of CAR-T Cell Therapy
   Several CAR-T products are approved internationally and in India. They differ mainly by the target protein they are engineered against and the
   specific costimulatory domain used in the receptor design.

India’s Homegrown Breakthrough — NexCAR19: Developed jointly by IIT Bombay and Tata Memorial Centre, NexCAR19 was approved as India’s first
indigenous CAR-T therapy in October 2023. Clinical trial results showed an overall response rate of 87.5%, with a majority of evaluable patients achieving
complete or partial response, and only a small number developing severe cytokine release syndrome. Because it is manufactured locally, it costs a fraction
of imported CAR-T products, making the therapy far more accessible to Indian patients.

3. Step-by-Step Procedure
   Step 1: Evaluation & Eligibility Screening
   Before starting, doctors run blood work, imaging, organ function tests (kidney, liver, heart, lung), and infection screening to confirm the patient can
   safely tolerate the therapy.
   Step 2: Leukapheresis (Blood/T-Cell Collection)
   Blood is drawn through a vein and passed through a machine that separates and collects T-cells, returning the rest of the blood to the body. This
   outpatient process usually takes 3–4 hours.
   Step 3: Genetic Engineering in the Lab
   The collected T-cells are shipped to a specialized lab where a virus is used to insert the CAR gene into the cell’s DNA, reprogramming it to
   recognize the target cancer protein.
   Step 4: Cell Expansion
   The engineered cells are multiplied in the lab over 2–4 weeks until there are enough — often tens to hundreds of millions — to be therapeutically
   effective.
   Step 5: Lymphodepleting Chemotherapy
   A short course of low-dose chemotherapy is given a few days before infusion to reduce existing immune cells, creating space for the new CAR-T
   cells to expand and function effectively.
   Step 6: CAR-T Cell Infusion
   The engineered cells are infused back into the patient through an IV, similar to a blood transfusion. This is usually a single, one-time infusion.
   Step 7: Hospital Monitoring
   Patients are closely monitored in hospital (often 1–3 weeks) for early signs of side effects such as cytokine release syndrome or neurological
   symptoms, since these tend to appear within the first 1–2 weeks.

4. Cost of CAR-T Cell Therapy in India
   CAR-T therapy costs in India vary widely depending on the product used (imported vs. indigenous), hospital, city, ICU requirements, and
   complications during recovery. Based on current data from hospitals and patient-cost aggregators:

For context, the same class of imported CAR-T therapy costs roughly $380,000–$525,000 in the United States — so treatment in India represents
savings of up to 80–90% even before accounting for indigenous options, which push the discount even further.

What Affects the Final Bill?
Product choice: Indigenous products cost significantly less than imported ones.
Hospital & city: Metro-city private hospitals typically charge more than government or Tier-2 city centers.
ICU/room category: Private rooms and extended ICU stays add cost.
Complications: Managing cytokine release syndrome or neurotoxicity can extend hospital stay and cost.
Pre-treatment workup: Consultation, imaging, and lab tests typically add a few lakh rupees.

5. Who Needs This Therapy (Indications)
   CAR-T therapy is generally reserved for patients whose cancer has relapsed after, or did not respond to, standard treatments like chemotherapy or
   stem cell transplant. Current approved and commonly treated indications include:
   Relapsed or refractory B-cell Acute Lymphoblastic Leukemia (ALL), typically in patients up to 25 years old
   Relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and other aggressive B-cell lymphomas
   Relapsed or refractory Multiple Myeloma (BCMA-targeted products)
   Certain cases of Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma, depending on center and trial availability
   Eligibility also depends on overall health, organ function, and absence of active uncontrolled infections, since the treatment temporarily weakens
   the immune system.
6. Risks and Side Effects
   Because CAR-T cells trigger a powerful immune response, side effects can be significant and require close hospital monitoring.

Cytokine Release Syndrome (CRS)
The most common side effect. As CAR-T cells multiply and attack cancer cells, they release large amounts of signaling proteins called cytokines,
causing fever, low blood pressure, and flu-like symptoms. Most cases are mild to moderate and manageable with medication, though severe CRS
can require ICU care.
Neurotoxicity (ICANS)
Some patients develop temporary confusion, difficulty speaking, or in rare severe cases, seizures. This typically resolves with treatment and close
monitoring.
Cytopenias (Low Blood Counts)
Reduced white blood cells, platelets, or red blood cells can persist for weeks, raising infection and bleeding risk.
Infection Risk
A weakened immune system during recovery increases vulnerability to infections, requiring preventive antibiotics/antivirals in many cases.

7. Benefits of CAR-T Therapy
   High response rates: Many trials report 70–90% overall response rates in patients who had exhausted other options.
   One-time treatment: Unlike ongoing chemotherapy cycles, CAR-T is typically a single infusion.
   Durable remission potential: Some patients achieve long-term, sustained remission.
   Option when other treatments fail: Offers hope for patients who have relapsed after chemotherapy or bone marrow transplant.
   Personalized medicine: Uses the patient’s own cells, reducing certain rejection-related risks compared to donor-cell approaches.

8. Top Hospitals Offering CAR-T Therapy in India
Tata Memorial Centre, Mumbai — government-linked center co-developer of NexCAR19
All India Institute of Medical Sciences (AIIMS), Delhi
Apollo Hospitals (multiple cities)
SMS Medical College & Hospital, Jaipur
Other major private cancer centers in Delhi, Mumbai, Chennai, and Hyderabad
Several of these centers are expanding CAR-T infrastructure, with combined annual treatment capacity expected to grow substantially over the
next few years as more indigenous products reach the market.

9. Frequently Asked Questions
   Q1. Is CAR-T cell therapy a cure for cancer?
   It is not guaranteed to be a permanent cure, but for many relapsed/refractory blood cancer patients it produces deep, sometimes long-lasting
   remission where other treatments had failed.
   Q2. How long does the entire process take?
   From initial cell collection to infusion, manufacturing typically takes 2–4 weeks, followed by 1–3 weeks of close hospital monitoring and several
   more weeks to months of recovery.
   Q3. Is CAR-T therapy available for solid tumors?
   Currently approved CAR-T products mainly target blood cancers. Research into solid tumor applications is ongoing but not yet widely available
   outside clinical trials.
   Q4. Why is CAR-T so much cheaper in India than in the US?
   Lower manufacturing, hospital, and labor costs, along with India’s development of indigenous CAR-T products like NexCAR19, have brought prices
   down significantly compared to Western markets.
   Q5. Does insurance cover CAR-T therapy in India?
   Coverage varies by insurer and policy; it is still an evolving area. Many hospitals help patients explore insurance pre-authorization, EMI options, or
   charitable funding.

The post CAR-T Cell Therapy in India appeared first on superspecialitycare.

Today, that reality has changed. Robotic cardiac surgery is transforming how heart conditions are treated — and India has emerged as one of the world’s most advanced destinations for this technology.

 What Is Robotic Cardiac Surgery?

Robotic cardiac surgery uses a surgeon-controlled robotic system (such as the da Vinci Surgical System) to perform precise heart operations through tiny keyhole incisions — sometimes less than 1 cm wide. The surgeon sits at a console, viewing a magnified 3D image of the heart, and controls robotic arms that move with far greater precision, range, and steadiness than the human hand alone.

This is not a robot “operating on its own.” It is the surgeon’s skill, amplified and perfected through technology.

 What Conditions Can Be Treated Robotically?

At Super Speciality Care, our cardiac specialists perform a wide range of robotic heart procedures, including:

1. Robotic-Assisted Heart Valve Repair & Replacement

Damaged or leaking heart valves — particularly the mitral valve — can now be repaired with unmatched precision through tiny incisions. Patients go home in days, not weeks.

2. Robot-Assisted Coronary Artery Bypass (CABG)

For patients with blocked coronary arteries, robotic bypass surgery restores blood flow to the heart without the need for a large sternum-splitting incision. Recovery is dramatically faster.

3. Atrial Septal Defect (ASD) Closure

Congenital holes in the heart — once requiring open-chest surgery — can now be closed robotically with minimal blood loss and virtually no visible scarring.

4. Cardiac Tumour Removal

Rare tumours of the heart, such as atrial myxomas, are now safely removable through robotic-assisted minimal-access techniques.

5. Arrhythmia Surgery

Abnormal heart rhythms caused by structural problems can be corrected using robotic precision that conventional surgery cannot match.

 Robotic vs Traditional Open-Heart Surgery: Key Differences

Traditional Open-Heart Surgery | Robotic Cardiac Surgery 

| Incision Size | 20–30 cm sternum cut | 3–4 small cuts (1 cm each) |

| Hospital Stay | 7–10 days | 2–4 days |

| Recovery Time | 6–12 weeks | 2–3 weeks |

| Blood Loss | Significant | Minimal |

| Pain Level | High | Significantly lower |

| Scarring | Large visible scar | Nearly invisible |

| Infection Risk | Higher | Much lower |

| Return to Work | 2–3 months | 3–4 weeks |

 Why India for Robotic Cardiac Surgery?

India has rapidly become a global hub for advanced cardiac care — and for good reason.

World-Class Surgeons

India’s cardiac surgeons are among the most experienced in the world. Many have trained at leading institutions in the US, UK, and Europe, and perform hundreds of robotic procedures annually.

Advanced Technology

Top hospitals in India are equipped with the latest generation robotic surgical systems, advanced cardiac imaging suites, and real-time physiological monitoring infrastructure — the same technology used in the best hospitals globally.

Cost Advantage

This is perhaps the most significant factor for international patients. Robotic cardiac surgery in India costs a fraction of what it does in the West:

USA: $80,000 – $1,50,000

UK: $60,000 – $1,00,000

India: $6,000 – $15,000

The quality is identical — or often superior. The cost difference is structural, not a reflection of care quality.

No Waiting Lists

In countries like the UK and Canada, patients can wait 6–18 months for elective cardiac surgery. In India, treatment can begin within days of arrival.

International Patient Support

Leading centres like SSC offer complete end-to-end international patient coordination — visa assistance, airport transfers, accommodation, dietary support, translator services, and post-treatment follow-up.

The SSC Advantage: Robotic Cardiac Care You Can Trust

At Super Speciality Care (SSC), we have helped patients from 20+ countries receive world-class robotic cardiac surgery in India. Our approach is built on three pillars:

Precision Technology

We use advanced robotic platforms equipped with Endo-Wrist instrumentation and real-time cardiac imaging, allowing our surgeons to work with sub-millimetre precision inside the beating heart.

Transparent, Honest Care

We believe in free pre-treatment estimates, no hidden charges, and complete clarity about your treatment plan, costs, and expected outcomes before you commit to anything.

Comprehensive Follow-up

Our care doesn’t end when you leave the operating theatre. We provide structured post-operative follow-up, telemedicine consultations, and coordination with your home country doctors to ensure a safe, smooth recovery.

What Our Patients Say

I was told I needed open-heart surgery for my mitral valve. My doctor in Germany said robotic surgery wasn’t possible in my case. At SSC, the team reviewed my case, explained the robotic approach clearly, and I was back home walking normally within 3 weeks. It was life-changing.

Patient from Germany

The cost of the same surgery in the US was over $120,000. At SSC, I paid less than $10,000 for the exact same procedure, with the same technology. The care was exceptional.

Patient from USA

Is Robotic Cardiac Surgery Right for You?

Robotic cardiac surgery is not suitable for every patient — your eligibility depends on the specific condition, its severity, your overall health, and other factors. This is why a thorough evaluation by an experienced robotic cardiac surgeon is the essential first step.

At SSC, we offer **free consultations** where our specialists review your medical reports, scans, and history to advise whether robotic surgery is the right option for you — with no obligation and no hidden costs.

 Frequently Asked Questions

Q: Is robotic cardiac surgery safe?

Yes. Decades of clinical evidence show robotic cardiac surgery has equal or better safety outcomes compared to open-heart surgery, with significantly lower complication rates.

Q: How long does the surgery take?

Depending on the procedure, robotic cardiac surgery typically takes 2–5 hours.

Q: When can I fly home after surgery?

Most international patients are cleared to fly home 7–14 days after robotic cardiac surgery, subject to their surgeon’s assessment.

Q: Do I need to speak Hindi to be treated in India?

No. SSC provides full English language support, plus interpreter services in multiple languages for international patients.

Q: How do I get a second opinion from SSC remotely?

Simply share your medical reports, echo reports, and angiography on WhatsApp. Our team will review your case and revert within 24 hours.

Take the First Step Today

Heart disease doesn’t wait — and neither should you. If you or a loved one has been diagnosed with a cardiac condition that may require surgery, speak to our robotic cardiac specialists today.

📞 Call / WhatsApp: +91 97173 38282

🌐 www.superspecialitycare.com

✅ Free Estimate    ✅ No Hidden Charges    ✅ 20+ Countries Served

Super Speciality Care (SSC) is a leading international patient coordination centre connecting patients worldwide with India’s finest robotic cardiac surgeons and hospitals. All treatments are performed by verified, credentialed specialists at accredited hospitals.

The post Robotic Cardiac Surgery in India: The Future of Heart Treatment Is Here appeared first on superspecialitycare.